Journal article icon

Journal article

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Abstract:

Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, tumors carrying BRCA2 inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focusing on genome-wide transcriptome alterations. Human cells in which BRCA2 expression is inhibited for 4 or 28 days are subjected to RNA-seq analyses revealing a biphasic response to BRCA2 abrogation...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Role:
Author
ORCID:
0000-0003-0981-8311
More from this funder
Name:
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
Grant:
722729
More from this funder
Name:
Wellcome Trust
Grant:
203141/Z/16/Z
Publisher:
Nature Research
Journal:
Nature Communications More from this journal
Volume:
10
Article number:
3143
Publication date:
2019-07-17
Acceptance date:
2019-06-18
DOI:
EISSN:
2041-1723
Pmid:
31316060
Language:
English
Keywords:
Pubs id:
pubs:1035646
UUID:
uuid:ad8a1cc3-e094-434a-94ac-75a970f960b4
Local pid:
pubs:1035646
Source identifiers:
1035646
Deposit date:
2019-12-04

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP